Tag:
Clarus Ventures
Latest Headlines
Latest Headlines
Vertex's new leader expected to diversify
Vertex Pharmaceuticals ( $VRTX ) will be getting its second new leader in two years as it seeks to become a more diversified drug company. Former Abbott Laboratories executive Jeffrey Leiden will
TetraLogic nabs $32M round for lead cancer therapy
Malvern, PA-based TetraLogic Pharmaceuticals has rounded up $32 million in Series C cash to back the development of its lead cancer drug, the early-stage TL32711. Clarus Ventures led the round with
Veteran entrepreneur gets backing for start-up
A former venture capitalist for Frazier Healthcare Ventures, Robert Overell, has structured an interesting round of funding for the Seattle-based startup PhaseRx. A trio of familiar funds, Arch
Clarus raises $660M for new life sciences fund
Clarus Ventures has raised $660 million for its second life sciences fund. Principals with the fund say they've invested 90 percent of the
Taligen raises a whopping $65M
Talk about big VC deals . Aurora, CO-based Taligen Therapeutics said today that it's expecting to receive
C&L: Fogelman new CFO at CytRx
CytRx Corporation has appointed Mitchell K. Fogelman as chief financial officer, effective immediately, replacing Matthew Natalizio, who plans to pursue other opportunities. Clarus Ventures
Pearl Therapeutics finds $15.5M in first VC round
Upstart Pearl Therapeutics, which is developing therapies for respiratory disorders, has raised $15.5 million in its first round. The Redwood City, CA-based biotech's round was co-led by New Leaf
VC: Novexel gains $64.8M in second round
Novexel gains $64.8M in second round
Press Release: Variation Biotechnologies Secures $35.7M in Series A Financing
Press Release: Variation Biotechnologies Secures $35.7M in Series A Financing
Variation Biotechnologies gains $35M in first round
Clarus Ventures has led a $35.7 million first round for Canada's Variation Biotechnologies. The biotech company's lead candidate is a new vaccine for influenza. ARCH Venture Partners and 5AM Ventures also took part in the round.
- here's the release on the venture round
ALSO: Horizon Therapeutics has raised an additional $15 million through a Series B financing to advance its lead product HZT-501, a …
